About this trial
evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70);
Pre-survival time > 6 months;
The pathological tissue was confirmed as NK/T cell lymphoma (the pathological report of the first three months of enrollment could be accepted) (Note: If there is any doubt about the pathological diagnosis, domestic third-party consultation could be organized);
Clinical stage Ⅰ to Ⅱ (CA stage) with at least one measurable lesion;
Disqualifiers
Refuse to collect blood samples;
Previous allergy to any of the drugs in the program;
Pregnant and lactating women;
Major diseases that the investigator believes can cause interference with the test;
Trial design
Single group
Treatments tested in this trial
Selinexor+pegaspargase+dexamethasone
DrugNuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
Treatment groups
Trial outcomes
Primary outcomes
CRR
The proportion of patients whose tumor volume has reduced to a predetermined value and can maintain the minimum time limit is the sum of complete mitigation.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Mingzhi Zhang
Lead sponsor
Zhengzhou University
Sponsor institution